Ashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnaksu R, Hosokawa H, et al. Bmi1 regulates memory CD4 T cell survival by way of repression with the Noxa gene. J Exp Med. 2008;205:1109?0. 37. Wang Y, Zang X, Wang Y, Chen P. High expression of p16INK4a and low expression of Bmi1 are related to endothelial cellular senescence inside the human cornea. Mol Vis. 2012;18:803?five. 38. Jiang L, Song L, Wu J, Yang Y, Zhu X, Hu B, et al. Bmi-1 promotes glioma angiogenesis by activating NF-B signaling. PLoS 1. 2013;eight:e55527. 39. Xu C-R, Lee S, Ho C, Bommi P, Huang S-A, Cheung ST, et al. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. Mol Cancer Res. 2009;7:1937?5. 40. Chen F, Chen L, He H, Huang W, Zhang R, Li P, Meng Y, Jiang X. Upregulation of microRNA-16 in glioblastoma inhibits the function of endothelial cells and tumor angiogenesis by targeting Bmi-1. Anticancer Agents Med Chem. 2015. Epub ahead of print. 41. Kawano Y, Moschetta M, Manier S, Glavey S, G g GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160?two. 42. Zhang H-W, Ding J, Jin J-L, Guo J, Liu J-N, Cephapirin Benzathine manufacturer Karaplis A, et al. Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice. J Bone Miner Res. 2010;25:640?2. 43. Xie C, Jin J, Lv X, Tao J, Wang R, Miao D. Anti-aging impact of transplanted amniotic membrane mesenchymal stem cells in a premature aging model of Bmi-1 deficiency. Sci Rep. 2015;five:13975. 44. Lin GL, Hankenson KD. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem. 2011;112:3491?01. 45. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, et al. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015;8:63. 46. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao J-J, Mani M, et al. Targeted disruption from the BCL9/-catenin complicated inhibits oncogenic Wnt signaling. Sci Transl Med. 2012;4:148ra117. 47. Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, et al. AV-65, a novel Wnt/-catenin signal inhibitor, effectively suppresses progression of several myeloma within a mouse model. Blood Cancer J. 2011;1:e43. 48. Bjorklund CC, Ma W, Wang Z-Q, Davis RE, Kuhn DJ, Kornblau SM, et al. Proof of a role for activation of Wnt/beta-catenin signaling within the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286:11009?0. 49. Tai YT, Chang BY, Kong S-Y, Fulciniti M, Yang G, Calle Y, et al. Bruton tyrosine L-Cysteine Endogenous Metabolite kinase inhibition is a novel therapeutic tactic targeting tumor inside the bone marrow microenvironment in multiple myeloma. Blood. 2012; 120:1877?7. 50. Kim K, Kong S-Y, Fulciniti M, Li X, Song W, Nahar S, et al. Blockade in the MEK/ ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010;149:537?9. 51. Spencer A, Yoon S-S, Harrison SJ, Morris SR, Smith DA, Brigandi RA, et al. The novel AKT inhibitor afuresertib shows favorable security, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124: 2190?. 52. Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical improvement. J Hematol Oncol. 2015;8:129. 53. Bolomsky A, Schreder M, Mei er T, Hose D, Ludwig H, Pfeifer S, et al. Immunomodulatory drugs thalidomide and lenalidomide impact osteoblast differentiation of human bon.